Estratab (.3 mg )

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved March 1998

Specific Treatments:

prevention of osteoporosis

General Information

Estratab (.3 mg ) has been approved for the prevention of osteoporosis.

Clinical Results

In a two-year clinical trial, women on .3 mg Estratab tablets showed increased bone mineral density over baseline in the spine, hip, and whole body.

Side Effects

Women taking this low dose also experienced fewer side effects, such as headache, nausea, breast tenderness, and vaginal bleeding, than women on higher doses.